MXPA02006554A - Minigenes optimizados y peptidos codificados por los mismos. - Google Patents

Minigenes optimizados y peptidos codificados por los mismos.

Info

Publication number
MXPA02006554A
MXPA02006554A MXPA02006554A MXPA02006554A MXPA02006554A MX PA02006554 A MXPA02006554 A MX PA02006554A MX PA02006554 A MXPA02006554 A MX PA02006554A MX PA02006554 A MXPA02006554 A MX PA02006554A MX PA02006554 A MXPA02006554 A MX PA02006554A
Authority
MX
Mexico
Prior art keywords
peptides encoded
vaccines
optimized
minigenes
optimized minigenes
Prior art date
Application number
MXPA02006554A
Other languages
English (en)
Inventor
Alessandro Sette
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of MXPA02006554A publication Critical patent/MXPA02006554A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
MXPA02006554A 1999-12-28 2000-12-28 Minigenes optimizados y peptidos codificados por los mismos. MXPA02006554A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17339099P 1999-12-28 1999-12-28
PCT/US2000/035568 WO2001047541A1 (en) 1999-12-28 2000-12-28 Optimized minigenes and peptides encoded thereby

Publications (1)

Publication Number Publication Date
MXPA02006554A true MXPA02006554A (es) 2003-09-22

Family

ID=22631795

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02006554A MXPA02006554A (es) 1999-12-28 2000-12-28 Minigenes optimizados y peptidos codificados por los mismos.

Country Status (14)

Country Link
EP (1) EP1242108B1 (es)
JP (2) JP2004512815A (es)
KR (1) KR100838507B1 (es)
CN (1) CN1437476A (es)
AT (1) ATE366582T1 (es)
AU (1) AU780064B2 (es)
BR (1) BR0017052B1 (es)
CA (1) CA2394748A1 (es)
DE (1) DE60035523T2 (es)
DK (1) DK1242108T3 (es)
ES (1) ES2288885T3 (es)
HK (1) HK1048068B (es)
MX (1) MXPA02006554A (es)
WO (1) WO2001047541A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
AU2002950183A0 (en) * 2002-07-12 2002-09-12 The Council Of The Queensland Institute Of Medical Research Expression of hydrophobic proteins
EP1578432A4 (en) * 2002-10-03 2008-07-30 Epimmune Inc HLA BINDING PEPTIDES AND USES THEREOF
WO2004031210A2 (en) 2002-10-03 2004-04-15 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
EP1687022A4 (en) * 2003-11-12 2008-02-13 Medical Res Council RENTA: HIV IMMUNOGEN, AND USES OF RENTA
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
AU2007314550A1 (en) * 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
JP5792630B2 (ja) 2009-01-28 2015-10-14 エピミューン，インコーポレイティド Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
GB0905519D0 (en) * 2009-03-31 2009-05-13 Biofortuna Ltd Assay method and device
CA2836494C (en) 2011-05-24 2023-01-03 Biontech Ag Individualized vaccines for cancer
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014059489A1 (en) 2012-10-19 2014-04-24 The Council Of The Queensland Institute Of Medical Research Improved human herpesvirus immunotherapy
US10155031B2 (en) 2012-11-28 2018-12-18 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CN105254719B (zh) * 2015-10-21 2018-07-13 黑龙江八一农垦大学 金黄色葡萄球菌trap蛋白的cd4+t细胞表位鉴定及其重组表位疫苗
CN112135908A (zh) * 2018-01-22 2020-12-25 国立传染病研究所长代表日本国 选择性cd8阳性t细胞诱导疫苗抗原
KR20210013105A (ko) * 2018-05-23 2021-02-03 그릿스톤 온콜로지, 인코포레이티드 공유 항원

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ290089A (en) * 1994-07-27 1999-05-28 Queensland Inst Med Res Recombinant polyepitope cytotoxic t lymphocyte (ctl) vaccines
JP4108126B2 (ja) * 1996-04-26 2008-06-25 リュクスウニヴェルシテート テ レイデン Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン
CA2250723C (en) * 1996-05-24 2012-07-17 Chiron Corporation Multiple epitope fusion protein
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
CA2685270C (en) * 1998-05-13 2014-07-29 Pharmexa Inc. Expression vectors for stimulating an immune response and methods of using the same

Also Published As

Publication number Publication date
JP2011168592A (ja) 2011-09-01
EP1242108A4 (en) 2005-11-02
DK1242108T3 (da) 2007-11-12
BR0017052A (pt) 2006-03-01
JP2004512815A (ja) 2004-04-30
CA2394748A1 (en) 2001-07-05
DE60035523T2 (de) 2008-03-20
AU2607501A (en) 2001-07-09
JP5628716B2 (ja) 2014-11-19
KR100838507B1 (ko) 2008-06-17
AU780064B2 (en) 2005-02-24
KR20020084424A (ko) 2002-11-07
HK1048068A1 (en) 2003-03-21
ES2288885T3 (es) 2008-02-01
ATE366582T1 (de) 2007-08-15
CN1437476A (zh) 2003-08-20
DE60035523D1 (de) 2007-08-23
HK1048068B (zh) 2008-02-22
EP1242108A1 (en) 2002-09-25
WO2001047541A1 (en) 2001-07-05
BR0017052B1 (pt) 2013-12-24
EP1242108B1 (en) 2007-07-11

Similar Documents

Publication Publication Date Title
HK1048068A1 (en) Optimized minigenes and peptides encoded thereby
AU2003296330A8 (en) Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2001034801A3 (en) Recombinant gelatin in vaccines
MY125202A (en) Vaccine
WO2003104273A3 (en) THERAPEUTIC EPITOPES AND THEIR USES
IL230101A0 (en) Treatment of pathologies that evade an immune response through the use of optimistic antibodies
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
DE60005953D1 (de) Stapelbare statische mischelemente
GB0123580D0 (en) Vaccine
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
WO2005039630A3 (en) Immunogenic compositions
EP1572087A4 (en) ANTIBODY TO CANCERANT TMEFF2 AND ITS APPLICATIONS
WO2004031210A3 (en) Optimized multi-epitope constructs and uses thereof
MXPA02012249A (es) Peptidos, composiciones y metodos para el tratamiento de burkholderia cepacia.
WO2001090366A3 (en) Human polynucleotides and polypeptides encoded thereby
AU2003245781A8 (en) Mhc class ii peptide epitope of 5t4 antigen
GB0004576D0 (en) Proteins
EP1316560A4 (en) NEW HUMAN HEAD CANCER ANTIGEN AND HIS GEN
EP1842549A3 (en) Optimized minigenes and peptides encoded thereby
ZA200205470B (en) Virus strains for the oncolytic treatment of cancer.
WO2002074332A3 (en) Method to enhance the immunogenicity of an antigen
CA98135S (en) Colander
AP2004002980A0 (en) The treatment of lipodystrophy.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: PHARMEXA INC.

HC Change of company name or juridical status

Owner name: ZILA BIOTECHNOLOGY, INC.

FA Abandonment or withdrawal